- Dr. Sellers is a prominent figure in cancer research, associated with the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School.
- He has contributed significantly to cancer genomics, particularly in identifying EGFR mutations in lung cancer and MITF as an oncogene in melanoma.
- Dr. Sellers' early academic influences and career in medicine were shaped by his education and experiences at institutions like Georgetown University and the University of California, San Francisco.
- His work at Novartis involved pioneering genetic and genomic approaches to cancer therapy, leading to the development of a cancer cell line encyclopedia and the approval of several drugs for clinical trials.
- Dr. Sellers returned to academia in 2017, focusing on collaboration and innovative research methods such as combination CRISPR screens.
- He emphasizes the importance of understanding why some patients achieve cures and aims to explore gene activators as potential therapeutics.
- Dr. Sellers balances his professional life with personal interests such as cycling, hiking, cooking, and spending time with his family.
First person profile: William Sellers, MD
Summary
Based in Cambridge, Massachusetts, Dr. Sellers is a core member of the Broad Institute of MIT and Harvard, a senior advisor to the president for experimental therapeutics at Dana-Farber Cancer Institute, and a professor of medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is widely recognized for his groundbreaking findings in cancer genomics and therapeutic drug discovery and his research that homes in on the functions of tumor suppressor genes and oncogenes and cancer's molecular pathways through the use of high-throughput genetic sequencing and other methods.
In the early 2000s, Dr. Meyerson, who is also a member of the Broad Institute and is currently the director of the Center for Cancer Genome Discovery at the Dana-Farber Cancer Institute, partnered with Dr. Sellers on a gene sequencing project. “Bill and I were talking about cancer genomes, and he said, ‘We should sequence the kinase genes where we might find something that's immediately treatable and could make a big difference in cancer,’” Dr. Meyerson recalls. “Bill has a lot of scientific courage—he just dives right in and is not deterred by anything.”
William Sellers, Dana Farber Cancer Institute, Harvard, melanoma
Related Topics
You May Also Like
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Article
Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys